EyePoint Pharmaceuticals, Inc. (EYPT) 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Investors who purchased EyePoint securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether EyePoint has violated federal securities laws.

On August 30, 2022, EyePoint disclosed that it had received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts. The subpoena demanded documents covering the Company’s sales practices for its postoperative inflammation treatment, DEXYCU. Following this news, EyePoint stock dropped.

If you are aware of any facts relating to this investigation or purchased EyePoint shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.